Welcome to our dedicated page for MyMD Pharmaceuticals news (Ticker: MYMD), a resource for investors and traders seeking the latest updates and insights on MyMD Pharmaceuticals stock.
MyMD Pharmaceuticals, Inc. (DE) (NASDAQ: MYMD) is a clinical-stage biopharmaceutical company that focuses on extending healthy lifespan through the development of innovative therapeutic platforms. The company is committed to addressing serious autoimmune and inflammatory diseases as well as age-related conditions.
Core Therapeutic Platforms:
- MyMD-1: This is a small molecule drug platform that aims to regulate the immunometabolic system by controlling tumor necrosis factor-alpha (TNF-α) and other pro-inflammatory cytokines. MyMD-1 is being developed to treat autoimmune diseases such as multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. Additionally, it targets age-related illnesses, including frailty and sarcopenia. The drug’s oral administration is a significant advantage over existing TNF-α inhibitors, which require injectable forms.
- Supera-CBD: This drug platform is based on a novel synthetic derivative of cannabidiol (CBD) that targets key receptors, including CB2 and opioid receptors, and inhibits monoamine oxidase. Supera-CBD is designed to cater to the rapidly expanding CBD market, addressing conditions such as epilepsy, pain, and anxiety/depression.
Recent Achievements and Current Projects:
MyMD Pharmaceuticals has made significant strides in its clinical trials, particularly with MyMD-1. In a recently completed phase 2 clinical trial, MyMD-1 successfully met its primary endpoints by reducing biomarkers common in chronic inflammatory diseases, such as TNF-α, IL-6, and sTNFR1. The drug also met all secondary endpoints related to safety and tolerability standards. Full study results are expected to be released in 2024.
The company has already submitted and received approval for three Investigational New Drug Applications for MyMD-1, which is now advancing in clinical programs for conditions like sarcopenia, rheumatoid arthritis, and Hashimoto's disease. With a unique oral dosing method, MyMD-1 offers a promising alternative to current TNF-α inhibitors, which typically require infusion or injection.
Partnerships and Future Outlook:
Through strategic partnerships and ongoing research, MyMD Pharmaceuticals aims to pioneer the development of therapies that not only manage symptoms but also extend the healthy lifespan of patients. With its robust pipeline and innovative approaches, MyMD Pharmaceuticals is well-positioned to make a significant impact in the field of autoimmune and age-related disease treatment.
For up-to-date news and developments, visit the StockTitan website.
MyMD Pharmaceuticals has entered into a material transfer agreement with Bascom Palmer Eye Institute to explore the use of MYMD-1 in treating traumatic optic neuropathy (TON). TON affects vision due to optic nerve injury, occurring in 1.5% to 4% of head trauma cases. The study is fully funded by Bascom Palmer, ranked #1 eye hospital in the U.S. for 20 consecutive years. MyMD’s MYMD-1, originally developed for autoimmune diseases, is positioned as a potential treatment for various conditions due to its novel mechanism.
MyMD Pharmaceuticals (NASDAQ: MYMD) announced progress in its Phase 2 clinical trial for MYMD-1, aimed at delaying aging and chronic inflammation in individuals over 65. All trial sites are now actively enrolling patients, with efficacy data anticipated in the second half of 2022. Previous Phase 1 results indicated a significant decrease in TNF-alpha levels in treated subjects. The aging treatment market is projected to exceed $600 billion by 2025, with no other FDA-approved drugs targeting aging disorders currently available.
MyMD Pharmaceuticals aims to transform the
MyMD Pharmaceuticals has announced an acceleration in patient dosing for its Phase 2 clinical trial of MYMD-1, a potential therapy for aging-related conditions. The study involves participants aged 65 and older and aims to assess the drug's efficacy and safety. MYMD-1 selectively modulates the immune response to address chronic inflammation, a significant factor in aging. With no FDA-approved treatments for aging disorders, the market could exceed $600 billion by 2025. Initial results from the trial are expected in the first half of 2022.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced that Dr. Adam Kaplin, Chief Scientific Officer, will appear on Cheddar News Network's "Cheddar Innovates" on March 24, 2022, at 11:50 AM ET. He will discuss the Company's Phase 2 clinical trial of MYMD-1, aimed at delaying aging and expanding healthspan, as well as insights into the projected $600 billion market. The episode will be available for replay on MyMD's website after airing.
MyMD Pharmaceuticals has initiated patient enrollment in a Phase 2 clinical trial for MYMD-1, a drug aimed at delaying aging and enhancing healthy lifespan. The trial's primary goal is to lower inflammatory proteins TNF-α and IL-6. Following successful Phase 1 results showing significant TNF-α reduction, the company anticipates efficacy data in the first half of 2022. With a growing market for aging treatments projected at $600 billion by 2025, MyMD aims to capitalize on this opportunity while exploring MYMD-1's potential in treating autoimmune diseases.
MyMD Pharmaceuticals announced positive results from a Phase 1 study of MYMD-1, demonstrating a statistically significant reduction in TNF-α levels, a key driver of aging, in healthy subjects. The study met its primary endpoints, confirming MYMD-1's efficacy. The FDA has approved TNF-α reduction as a primary endpoint for an upcoming Phase 2 trial, anticipated to start in the first half of 2022. With a growing market for aging therapies projected to exceed $600 billion by 2025, MYMD-1 may offer a distinct profile compared to existing TNF-α blockers.
MyMD Pharmaceuticals (NASDAQ: MYMD) has expanded its intellectual property for MYMD-1, now covering three additional U.S. patents, bringing the total to 16. These patents protect MYMD-1's use in treating sarcopenia, a condition affecting 40% of the elderly, linked to severe health issues. The company is launching a Phase 2 trial for MYMD-1 targeting sarcopenia, with the U.S. market for aging-related disorders expected to exceed $600 billion by 2025. MyMD aims for MYMD-1 to become a leading drug in delaying aging and managing related diseases.
MyMD Pharmaceuticals has announced that its investment company, Oravax Medical, signed a Cooperation and Purchase Agreement with Vietnam's Tan Thanh Holdings for an initial pre-order of 10 million doses of an oral COVID-19 vaccine currently under development. The deal also allows for significant follow-on orders. Oravax's vaccine targets less mutable proteins and has benefits in logistics due to simplified storage requirements. MyMD holds a 13% stake in Oravax, along with a 2.5% royalty on future net sales. This agreement may boost revenue potential for both companies in the ASEAN region.
MyMD Pharmaceuticals (Nasdaq: MYMD) announced participation in two upcoming investor conferences in December 2021. At the Benchmark Company Discovery Conference on
FAQ
What is the current stock price of MyMD Pharmaceuticals (MYMD)?
What is the market cap of MyMD Pharmaceuticals (MYMD)?
What is MyMD Pharmaceuticals, Inc.?
What are the main therapeutic platforms developed by MyMD Pharmaceuticals?
What is MyMD-1?
What is Supera-CBD?
What recent achievements has MyMD Pharmaceuticals made?
What conditions is MyMD-1 being developed to treat?
How is MyMD-1 administered?
What are the potential benefits of Supera-CBD?
Has MyMD Pharmaceuticals received any regulatory approvals?
What is the future outlook for MyMD Pharmaceuticals?
